1. Novo Nordisk goes on a diet

Novo Nordisk is losing about 165,000 pounds to decrease its risk of Type II bad financials. That’s InsightCity’s estimate for the combined weight of the 1,000 people being let go from the company to remain competitive in the face of increasing competition in the diabetes market and pricing pressures in the U.S. Along with its slim-down in staff will come the trimming of its diabetes prospects in development, according to Chief Executive Officer Lars Rebien Soerensen. According to Soerensen, products without substantial innovation will be culled from the pipeline to maximize their candidates’ reimbursement potential. Remember, to reduce your risk of needing one of their new, innovative products, eat this. Not this.